Startup Highlight: AI CureDrug adherence is a huge focus for pharmaceutical companies and health syst
| |
| |
| May 13 - Issue #12 Curated by R. Scott Munro, the latest news and information about startups and innovations in healthcare. |
|
| Drug adherence is a huge focus for pharmaceutical companies and health systems, both in terms of trial design/outcomes and in terms of actual health outcomes and readmissions. AI Cure is taking a novel, video based approach to confirming drug adherence that will have HUGE impacts for all the stake holders involved. The company has developed an algorithm that can detect a particular pill being ingested by a patient remotely. The kicker: they’ve actually done studies to prove its efficacy relative to traditional adherence mechanisms. It will be very fun to watch this company over time. As always, if you come across news, announcements, videos, or podcasts that you think the other 4,800+ subscribers would benefit from, e-mail me at scott.munro@startupdigestmail.com or tweet @R_Scott_Munro and subscribe to the digest, here. If you have feedback/suggestions, please let me know, here. PS - so sorry I missed last week, I’ve been traveling. I tried to include some extra goodies this week as compensation! |
|
| |
Garage Biotech: New drugs using only a computer, the internet and free online data This article really demonstrates the brave new world of pharmaceutical development from using genetics for drug repositioning to “ordering” tests using CROs and other organizations. It is quite an interesting look at all the tools at a researchers disposal in today’s age. |
How Blockchain Is Helping Genomics Research I have been trying to wrap my head around how blockchain will end up impacting health care. I’ve had a couple articles on the digest in the past, but I believe this piece offers a new perspective on the research and IP implications for the technology. I honestly still need someone to have a 90 minute conversation with my about the technology before I can get a better grasp of its implications. |
A simple way for the government to curb inflated drug prices This is a very interesting take on one way the government could lower drug costs: a legal tool similar to imminent domain but for patents. I have incredibly mixed feelings about is strategy,and don’t have the right answer for soaring drug costs, but I imagine if this strategy was used we would see some fairly negative consequences on the incentives for drug development. |
Bundling Healthcare Payment: Driving Value-Based Care Dr. Mazanec has a good overview of some new bundled care initiatives in the joint and hip space from CMS as well as an overview of the impetus for bundled care more generally. He has a brief overview of Health IT’s role in this world but honestly I think he isn’t expansive enough in his thinking. Beyond telemedicine, there are a whole slew of technologies (connected implants, better physical therapy applications, care coordination and discovery tools) that will also play a huge part in the ACO shift, not just EMRs and telemedicine. Still worth the read though. |
The Digital Health Accelerator Database Franziska Siefert had reached out to me some time ago looking for some information on global digital health accelerators, she has since put together (and plans to maintain) an incredibly comprehensive list of digital health focused accelerators from around the world. This is quite a useful resource for anyone in the space. |
Asthma And Injustice On Chicago's Southeast Side Dr. Kohar Jones writes a great reminder about the enviormental impacts of health care in this piece on asthma in Chicago’s south side. As entrepreneurs and technologists, we often think there is a technical solution to every problem. I wanted to include this as another reminder that when it comes to health care there is a lot that needs to be done to simply take care of an individual’s environment and well-being that no app can solve. |
Hospital Market Power Drives Private Payer Prices This article highlights a great study by Stuart Craig at UPenn. A lot of his points are fairly well known (cost variance for care, etc); however, two take aways are worth noting: 1) Medicare data is not a good substitute for private insurance data and there can be quite large discrepancies between the two and 2) Monopoly hospitals often negotiate much higher insurance payments from payers than non-monopoly hospitals. As we continue to see large health system consolidation, that second point will become increasingly important. |
| |
“Finally, we find that the strongest predictor of higher prices is the market power of hospitals. In particular, monopoly hospitals (hospitals without competitors within a 15 mile radius) negotiate prices with insurers that are 15% higher on average when compared to those with three or more competitors. We also find that clinical quality plays a very small role in determining price.” - Stuart Craig, UPenn |
| |
R. Scott Munro - Utility Infielder @ DocMatter I am a classical languages nerd turned digital health geek. I spend my days researching medical device, pharmaceutical, and biotech companies + helping clinicians efficiently collaborate. I have a passion for the intersection of health and technology, and wholeheartedly believe we are at the beginning of the most exciting eras of health care. |
|
| Do you enjoy receiving this? Please share it: |
Carefully curated by Health Startup Digest with Revue If you were forwarded this newsletter and you like it, you can subscribe here. If you don't want these updates anymore, please unsubscribe here. |
Tweet 
Share 
No comments:
Post a Comment